-
December 05, 2025Elpiscience Presents Phase I Data for First-in-Class ES014 (CD39/TGF-βBispecific) in Oral Session at ESMO Asia
On December 5, 2025, Elpiscience, a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies, presented phase I clinical trial results for its internally developed b...
-
November 28, 2025Preview | Oral Presentation at ESMO Asia 2025: First-in-Human Results of ES014, the World’s First CD39/TGF-β Bispecific Antibody, as Monotherapy in Advanced Solid Tumors to Be Unveiled
Elpiscience announced that the first-in-human Phase I clinical results of ES014, the world’s first-in-class CD39/TGF-β bispecific antibody developed in-house, will be presented as an oral p...
-
November 21, 2025Highlight Recap | Elpiscience Showcases Three Innovative Research Studies at SITC 2025, Demonstrating Original Innovation on the Global Academic Stage
From November 5 to 9, the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was grandly held at National Harbor, Maryland, USA. As one of the world’s largest and most influen...
-
October 20, 2025Elpiscience to Showcase Three Innovative Research Studies at the SITC 2025 Annual Meeting
Elpiscience Biopharmaceuticals today announced that it will showcase three cutting-edge research studies through poster presentations at the 40th Annual Meeting of the Society for Immunotherapy of Can...
-
October 13, 2025Leading Cross-Boundary Dialogue, Decoding Cutting-Edge Trends: “International Immunology Innovation Symposium” Successfully Held in Hangzhou
On September 29, 2025, Elpiscience, in collaboration with The Westlake University School of Medicine , the Chinese Society of Molecular Immunology, and Biomedical Innovation Group(BiG), successful...
-
September 03, 2025Symposium of Immunology Innovations 2025
Elpiscience will co-host the "Symposium of Immunology Innovations: From Discovery to Therapy in Cancer and Autoimmune Diseases" on September 29, 2025, together with the School of Medicine at...